【佳学基因检测】在癌症中靶向 p53

品牌基因检测价格表还有吗

比较做了备注《Curr Med Chem Anticancer Agents》在 2001 Aug;1(2):151-61发表了一篇题目为《在癌症中靶向 p53》肿瘤靶向药物治疗基因检测临床研究文章。该研究由P Chène 等完成。促进了肿瘤的正确治疗与个性化用药的发展，进一步强调了基因信息检测与分析的重要性。

肿瘤靶向药物及正确治疗临床研究内容关键词：

0

肿瘤靶向治疗基因检测临床应用结果

p53功能的丧失是癌症中非常重要的事件。肿瘤中缺乏功能性 p53 有利于癌症发展，并且有人认为它也会影响化学疗法和放射疗法的功效。因此，p53 通路是学术界和工业界都在进行深入研究的主题，以鉴定针对 p53 改变的肿瘤的新化合物。目前正在研究不同的策略。它们可以分为两组：生物策略和化学策略。生物学策略利用免疫系统来消除过度表达 p53 突变体的肿瘤。或者，他们使用在肿瘤或工程病毒中传递功能性 p53 基因的载体，选择性地靶向 p53 缺陷细胞。化学策略基于稳定或激活 p53 突变蛋白、抑制 p53 和 hdm2 之间的相互作用或作用于 p53 结合伴侣蛋白的化合物的设计。在本次审查中，将分析这些不同方法的当前进展。

肿瘤发生与反复转移国际数据库描述：

The loss of p53 function is a very important event in cancer. The absence of a functional p53 in tumours favours cancer development, and it has been suggested that it also influences the efficacy of both chemotherapy and radiotherapy. The p53 pathway is therefore the subject of intense research, both in academia and in industry, to identify new compounds targeting tumours with an altered p53. Different strategies are currently under investigation. They can be divided into two groups: biological and chemical strategies. The biological strategies utilise the immune system to eliminate the tumours overexpressing p53 mutants. Alternatively they use vectors delivering a functional p53 gene in tumours or engineered viruses, which selectively target p53-defective cells. The chemical strategies are based on the design of compounds that stabilise or activate the p53 mutant proteins, inhibit the interaction between p53 and hdm2, or act on the p53-binding chaperone proteins. In this review, the current progress in these different approaches will be analysed.